CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Mantle Cell Lymphoma.

Related Posts

STAT+: New Biden science agency ARPA-H launches first p...

May 19, 2023

Nitric oxide by NOxy Health Products for Diabetic Foot ...

Oct 3, 2023

STAT+: Private equity firm offers $5.8 billion buyout o...

Feb 27, 2024